The e-twenty-six family in hepatocellular carcinoma: moving into the spotlight
TABLE 1 The expression of the ETS transcription factors in HCC and their association with clinical-pathological features and patients' survival. BET inhibitors, some of which have been in clinical trials, could suppress the transcriptional activity and expression of ETS factors.